Related references
Note: Only part of the references are listed.Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension*
Paolo Mulatero et al.
JOURNAL OF HYPERTENSION (2020)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldn't Ignore It!
Martin Reincke
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Regulation of the Hypothalamic- Pituitary-Adrenocortical Stress Response
James P. Herman et al.
COMPREHENSIVE PHYSIOLOGY (2016)
Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy
Christoph D. Schumacher et al.
JOURNAL OF HYPERTENSION (2013)
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt
William B. Lea et al.
KIDNEY INTERNATIONAL (2009)
Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism
Cristiana Catena et al.
HYPERTENSION (2007)
Aldosterone synthase inhibitor ameliorates angiotensin II - Induced organ damage
A Fiebeler et al.
CIRCULATION (2005)
Comparison of active renin concentration and plasma renin activity for the diagnosis of primary hyperaldosteronism in patients with an adrenal mass
N Unger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Drugs targeting the renin-angiotensin-aldosterone system
MA Zaman et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Share Paper
